Ubaid Ansari, Meraj Alam, Dawnica Nadora, Zohaer Muttalib, Vincent Chen, Isabel Taguinod, Megan FitzPatrick, Jimmy Wen, Zaid Ansari, Forshing Lui
{"title":"Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review.","authors":"Ubaid Ansari, Meraj Alam, Dawnica Nadora, Zohaer Muttalib, Vincent Chen, Isabel Taguinod, Megan FitzPatrick, Jimmy Wen, Zaid Ansari, Forshing Lui","doi":"10.3934/Neuroscience.2024010","DOIUrl":null,"url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.</p>","PeriodicalId":7732,"journal":{"name":"AIMS Neuroscience","volume":"11 2","pages":"166-177"},"PeriodicalIF":3.1000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230861/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/Neuroscience.2024010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.
肌萎缩性脊髓侧索硬化症(ALS)是一种致命而复杂的神经退行性疾病,会影响中枢神经系统内的上下运动神经元,导致其进行性破坏。尽管进行了广泛的研究,但这种多发性疾病的发病机制仍然难以捉摸。美国食品和药物管理局(FDA)已批准七种药物用于治疗 ALS 并减轻其相关症状。这些获得 FDA 批准的治疗药物是 Qalsody、Relyvrio、Radicava、Rilutek、Tiglutik、Exservan 和 Nuedexta。本综述全面总结了这七种药物的作用机制、剂量和临床表现对 ALS 的影响。每种药物都提供了治疗 ALS 的独特方法,旨在减轻患者的症状负担并延缓病情发展,从而改善这种神经系统疾病患者的生活质量。然而,尽管在药物干预方面取得了这些进展,但找到彻底治愈 ALS 的方法仍然是一项重大挑战。对 ALS 病理生理学和治疗途径的持续研究仍然势在必行,这就需要进一步的研究合作和创新方法,以揭示这种使人衰弱的疾病的复杂机制。
期刊介绍:
AIMS Neuroscience is an international Open Access journal devoted to publishing peer-reviewed, high quality, original papers from all areas in the field of neuroscience. The primary focus is to provide a forum in which to expedite the speed with which theoretical neuroscience progresses toward generating testable hypotheses. In the presence of current and developing technology that offers unprecedented access to functions of the nervous system at all levels, the journal is designed to serve the role of providing the widest variety of the best theoretical views leading to suggested studies. Single blind peer review is provided for all articles and commentaries.